This article is more than 5 years old. Information may no longer be current.
Top stories in cardiology: ESC Congress presentations that may impact clinical practice, evolocumab effective for high-risk acute coronary syndrome
Among the top stories in cardiology last week were a preview of presentations from the European Society of Cardiology Congress that could affect clinical practice, and a randomized clinical trial presented at the ESC Congress that found evolocumab was well-tolerated and substantially reduced LDL levels when combined with statin therapy.
Other highlights included data presented at the ESC Congress that found clopidogrel significantly reduced bleeding in patients aged 70 years and older with non-ST-elevation acute coronary syndrome, study findings that suggested the decline in heart disease-related deaths is slowing, and the FDA providing a pathway to market Revascor, an investigational cell therapy used to prevent post-implantation mucosal bleeding in patients with end-stage chronic heart failure.
ESC Congress preview: Anticipated trials, presentations may potentially impact clinical practice
The European Society of Cardiology Congress, which is being held Aug. 31 to Sept. 4 in Paris, will feature late-breaking clinical science presentations that have the potential to have a significant impact on CV care. Read more.
Evolocumab shows benefit for high-risk ACS: EVOPACS
PARIS — In the first randomized trial designed to assess a PCSK9 inhibitor in patients with high-risk ACS, the addition of evolocumab to statin therapy was well tolerated and substantially reduced LDL levels, with most patients within currently recommended target levels following treatment. Read more.
POPular AGE: Clopidogrel remains an option for elderly with ACS
PARIS — New data from the POPular AGE study support the use of clopidogrel over ticagrelor and prasugrel, based on significant reduction in bleeding, in patients aged 70 years and older with non-ST-elevation ACS. Read more.
Heart disease deaths declining, but not as fast as before
Researchers have determined that the decline of age-adjusted mortality due to heart disease is slowing, which may mean that the American Heart Association’s strategic goal of a 20% reduction by 2020 is becoming more unlikely. Read more.
FDA provides pathway to BLA approval for chronic heart failure cell therapy
The FDA has established a pathway to marketing for Revascor, an investigational cell therapy used for the prevention of post-implantation mucosal bleeding in patients with end-stage chronic heart failure who require a left ventricular assist device. Read more.